(DNTH)

Reporting relationship: Director
Issuer ticker: DNTH
Reported as of: 21 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2026, 16:30:05 UTC
Prior SEC filing: 23 Jan 2026
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Veness, as attorney-in-fact for Jonathan Violin

Key filing fact

Jonathan Violin filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 22 May 2026.

Key facts

This page summarizes Jonathan Violin's Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 May 2026, 16:30.

Change

Previous filing in this sequence was filed on 23 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001730615 Primary reporting owner

Violin Jonathan

Relationship: Director
Address: C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK
Signature: /s/ Adam Veness, as attorney-in-fact for Jonathan Violin
Signature date: 22 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNTH transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +6,090
Change %
Price: $0.000000^*
Shares after: 6,090
Date: 21 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,090
Exercise price: $89.63
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.